Restriction fragment length polymorphism: the RFLP method

Restriction fragment length polymorphism analysis is a molecular genetic technique in which DNA is cut with specialized enzymes and the length of the resulting fragments is then measured. If the region being analyzed contains a sequence change, the fragments may become longer, shorter, or even change their sequence altogether after cleavage. [1]

The biological basis of the method is simple: restriction enzymes recognize strictly defined short DNA sequences. When a single-nucleotide variant or a small insertion or loss of nucleotides creates or destroys such a region, the pattern of the fragments changes, and the laboratory detects this through electrophoresis. [2]

The method is codominant, meaning it can detect both alleles in a heterozygous carrier. This is an important advantage, as the laboratory can distinguish between the normal variant, the altered variant, and carrier status based on the band pattern alone. [3]

The classic analysis method was historically performed on genomic DNA, followed by transfer of fragments to a membrane and hybridization with a probe. More recently, the amplification method has become more common, whereby a polymerase chain reaction is performed first, and then the short amplified fragment is cleaved, significantly simplifying the workflow and reducing the amount of DNA required. [4]

Historically, this is one of the fundamental methods of molecular genetics. However, in 2026, its role has changed: for many broad diagnostic tasks, gene panels, exome and genomic sequencing have become the primary platform, while restriction fragment length polymorphism analysis is more often used as a narrow, targeted test for pre-known variants. [5]

Table 1. What exactly does the method reveal?

Genetic situation	What happens after the restriction enzyme acts?	What the laboratory sees
The recognition site has been saved	The fragment splits	Shorter stripes appear
The recognition site is lost	The fragment does not split	A longer streak is maintained
Heterozygous state	Some molecules are cut, some are not.	Both long and short stripes are visible
Additional option next to the site	The picture may change unexpectedly	An atypical pattern is possible

The table summarizes the basic principle of the method: it does not “read” the entire gene sequence, but indirectly judges the variant by the change in the length of fragments after restriction. [6]

When is the test scheduled today?

The most logical application of the method today is the targeted testing of a single, known variant or a small group of variants, if a suitable restriction enzyme site exists for them. In this situation, the method remains understandable, technically accessible, and relatively inexpensive. [7]

One current example remains genetic testing for thrombophilia factors, primarily variants in the factor V and prothrombin genes. A recent study from 2026 shows that this method remains in demand in laboratories with low sample throughput, especially when it is important to inexpensively test for these two clinically significant variants while simultaneously incorporating cleavage control. [8]

Another niche is immunohematology and the identification of certain blood group antigens. For the Kell system, it is noted that the amplification version of the method helps identify rare phenotypes that are not always reliably determined by serological approaches alone. [9]

The method has also found its place in infectious disease diagnostics and epidemiological surveillance. Publications in 2024 and 2025 demonstrate its use for rapid and cost-effective detection of Mycobacterium tuberculosis complex, genotyping of Giardia duodenalis, and tracking of coronavirus variants in settings where cost and simplicity are critical. [10]

However, if the task is broader—for example, searching for an unknown hereditary cause of a disease, constructing a tumor mutation panel, or analyzing multiple loci simultaneously—this method is usually not the optimal first choice. For such scenarios, clinical genomics relies on sequencing as the primary technological platform. [11]

Table 2. Where the method is appropriate and where it is not

Clinical task	How appropriate is the method?	Why
Checking 1 known variant	High relevance	Fast, cheap, easy to interpret
Testing for thrombophilia factors factor V and prothrombin	Highly suitable for small laboratories	Well suited for a small number of targets
Determination of individual blood antigens	Moderate relevance	Useful as a molecular adjunct to serology
Species and variant identification of some pathogens	Moderate relevance	Particularly useful when resources are limited
Search for an unknown mutation in a large gene	Low relevance	The method is too narrow
Tumor profiling and large panels	Low relevance	More extensive sequencing technologies are needed

This table reflects modern practice: the method is alive not as a universal platform, but as a targeted tool for a narrowly defined question. [12]

How is research conducted in a laboratory?

Blood, saliva, or a swab from the inside of the cheek are typically used for analysis, and less commonly, other tissues are used if clinically required. After collecting the sample, the laboratory isolates DNA, which then becomes the subject of further analysis. [13]

The next step is selecting a precise target. The laboratory must know in advance which variant is being searched for, which DNA region needs to be amplified, and which restriction enzyme can distinguish between the normal and altered sequences. If a natural site does not exist, the construct is sometimes tailored to create an artificial site using a primer. [14]

A polymerase chain reaction is then performed to obtain a sufficient number of copies of the desired fragment. The amplicon is then treated with a selected restriction enzyme to cut it only where the corresponding recognition site is present. [15]

The cleavage products are separated by electrophoresis, after which the band pattern is assessed. At this stage, controls are essential: positive and negative samples, as well as a control of the cleavage itself, as the lack of proper controls is one of the main causes of erroneous conclusions. [16]

The final laboratory result is not simply a photograph of the gel, but a formalized conclusion about the genotype at a specific position. If the band pattern appears atypical, the clinical significance is high, or the result is inconsistent with the clinical picture, the laboratory should repeat the test and, if necessary, confirm the conclusion by direct sequencing. [17]

Table 3. Main stages of the laboratory process

Stage	What does the laboratory do?	Why is this necessary?
1	Selects a specific variant and DNA region	To ensure that the test answers a precise clinical question
2	Extracts DNA from a sample	To obtain suitable material
3	Amplifies the desired fragment	To increase the amount of target DNA
4	Treats the amplicon with restriction enzyme	To distinguish between variants by fragment length
5	Performs electrophoresis	To see a set of stripes
6	Evaluates controls and forms a conclusion	To eliminate technical error

The stages are important because the reliability of the result depends not on one action, but on the entire chain - from the choice of the target to the quality control of the cleavage. [18]

Patient preparation and material for analysis

For most DNA-based tests, special preparation is minimal. If blood is the sample, no special restrictions are usually required, whereas for saliva and cheek swabs, the lab may ask you to temporarily fast, drink, and rinse your mouth before sampling. [19]

From a practical standpoint, the patient's primary concern is not the diet but the precise formulation of the question. This method is useful when it is known that a specific variant is being sought, rather than any possible mutation in a gene or group of genes. [20]

If the test concerns a hereditary risk, it is advisable to have a physician or genetic counselor evaluate your personal and family history before the test. For clinical genetic testing, such pre-screening enhances the meaningfulness of the test and helps avoid tests that are technically correct but chosen inappropriately. [21]

The physical risks of the test itself are usually minimal and depend primarily on the method of sample collection. Blood may be accompanied by short-term soreness or bruising, while saliva and cheek swabs pose virtually no physical risk. [22]

For the laboratory, the key preparatory issues are different: the quality of the isolated DNA, the absence of cross-contamination, proper controls, and the correct polymerase chain reaction setup. These factors are what most often determine whether the result will be legible and reliable. [23]

Table 4. What material is used and how to prepare it

Material	What is usually required before collection?	Peculiarities
Venous blood	Usually no special training is needed.	The most common clinical material
Saliva	They often ask you not to eat or drink for 30 minutes.	Convenient for non-invasive collection
Cheek swab	They often ask to rinse their mouth.	A simple and painless way
Other fabrics	According to individual indications	Depends on the clinical task

The table shows that patient preparation is usually simple, and the main difficulty of this analysis is not at the sampling stage, but in the laboratory part. [24]

Interpretation of results, limitations and typical errors

The classical logic of interpretation is as follows: if the recognition site is present, the fragment is cut; if absent, it remains intact. A heterozygous carrier simultaneously displays bands corresponding to both variants, making the method convenient for distinguishing between the three main genotypes. [25]

One of the most well-known technical problems is incomplete digestion. If the restriction enzyme doesn't work completely, a long fragment may remain in the sample, and the lab risks mistaking this pattern for the presence of an altered allele, when in fact it's a technical glitch. [26]

Another problem is additional sequence changes near the target position. These can affect restriction enzyme recognition, primer binding, or the expected banding pattern, leading to an atypical result that cannot be interpreted from the template. [27]

The main limitation of the method is its narrow scope. It does not scan the entire gene, does not search for unknown variants across the entire coding sequence, is poorly suited for large panels, and is not an optimal platform for tumor profiling or comprehensive diagnostics of rare inherited diseases. [28]

Therefore, a clinically significant result should always be interpreted in the context of the indications, family history, and other data. If the clinical picture is controversial, the clinical cost of error is high, or the diagnostic objective is broader, confirmation by another validated method, most often sequencing, is preferable. [29]

Table 5. Main limitations and sources of errors

Problem	What's happening	Possible consequence	What reduces the risk
Incomplete cleavage	The fragment is not cut completely	False conclusion about the genotype	Split control
Sample contamination	Foreign DNA gets into the sample	False positive result	Separate work areas and negative controls
Non-specific amplification	The wrong area is being strengthened	Unreadable gel	Optimization of primers and conditions
Additional option near the target	The stripe pattern changes	Misinterpretation	Re-statement and confirmation
Too broad a clinical question	The method checks too little	Diagnostic pass	Choosing a broader test

The table emphasizes the main principle: this method is reliable only when the clinical question is narrow and laboratory control is strict. [30]

How does the method differ from other molecular tests and what is its place in 2026?

Compared to allele-specific polymerase chain reaction and real-time polymerase chain reaction, this method typically requires more manual steps because amplification requires a separate restriction step and subsequent electrophoresis. This is why modern, rapid platforms often offer advantages in terms of speed, ease of automation, and ease of interpretation. [31]

Compared to direct sequencing, the difference is even more fundamental. Sequencing reveals the actual nucleotide sequence in the region being studied, whereas restriction fragment length polymorphism analysis only indirectly identifies a variant based on changes in band length, so it is always narrower in coverage and depends on the presence of a suitable restriction enzyme site. [32]

For broad-based genetic diagnostics, current clinical genomics standards already focus on gene panels, exome, and genomic sequencing. The American College of Medical Genetics and Genomics considers sequencing to be the primary platform for clinical genomic diagnostics, and for children with congenital anomalies, developmental delays, and intellectual disabilities, exome and genomic sequencing are recommended as first- or second-line tests. [33]

In oncology, the shift is even more noticeable. Modern molecular oncology relies on technologies capable of simultaneously assessing multiple driver mutations, biomarkers for targeted therapy, and molecular signatures of resistance, while targeted restriction analysis is only suitable for very specific applications. [34]

Nevertheless, the method cannot be considered "dead." In 2024, 2025, and 2026, studies continue to be published that use it as a low-cost and effective tool for low-volume laboratories, local genotyping programs, infectious disease diagnostics, and certain specialized clinical applications. In 2026, its place can be summarized as follows: not a universal modern platform, but a useful, targeted method where the target is known, the budget is limited, and a broad molecular search is not required. [35]

Table 6. Comparison with alternatives

Method	What does it cover?	Strengths	Weaknesses	Best use today
Restriction fragment length polymorphism analysis	1 or more pre-known loci	Cheapness, simplicity, clear design	Narrow scope, manual steps, risk of splitting errors	Spot checking of known variants
Allele-specific polymerase chain reaction	Some known variants	Faster, fewer manual steps	Also a narrow scope	Fast targeted analysis
Real-time polymerase chain reaction	Individual options and small sets of goals	Automation, speed	Higher cost of equipment	Low-volume routine clinical panels
Direct sequencing	A small section of a gene	The exact sequence is visible	Smaller in scale than larger panels	Confirmation and analysis of small areas
Exome and genomic sequencing	Very wide coverage	High diagnostic value for complex tasks	More complicated, more expensive, requires interpretation	Rare diseases, large panels, comprehensive diagnostics

The comparison shows that the choice of method should be determined not by the laboratory's habits, but by the clinical question and the required depth of search. [36]

Frequently Asked Questions

Is this a blood test or a genetic test?

This is a genetic analysis that is most often performed on a sample of blood, saliva, or cheek swab. That is, blood is only one possible source of DNA, and not the essence of the method. [37]

Does this method show all mutations in a gene?

No. The method is usually targeted to one specific site and only works when the change can be distinguished through a restriction site or a specially designed assay.[38]

Can it be used to search for an unknown cause of a hereditary disease?

Usually not, because this requires a broader molecular search. In such situations, clinical practice increasingly uses gene panels, exome, or genomic sequencing. [39]

Do I need to come on an empty stomach?

If the sample is blood, special preparation is often not required. For saliva and cheek swabs, the lab may ask you to temporarily fast, drink, and rinse your mouth before collection. [40]

Can the result be false?

Yes, as with any laboratory test. The most common causes of error for this method are incomplete digestion, as well as sample contamination and incorrect control setup. [41]

Is the method suitable for oncological mutations?

Only for very specific tasks. Modern oncology often requires methods that simultaneously evaluate multiple clinically significant mutations and biomarkers, so broader sequencing platforms and other modern molecular approaches play a key role. [42]

Why is this method still used if there are more modern technologies?

Because for a specific task, it remains inexpensive, technically understandable, and fully functional. This is especially important for low-volume labs and healthcare systems, where it is necessary to test a small set of pre-defined variants without deploying an expensive, large-scale panel. [43]

Can this analysis replace sequencing?

Not at all. It may be a good spot test, but it is no replacement for methods that read the DNA sequence itself and allow one to look for unknown or multiple variants. [44]

Conclusion

Restriction fragment length polymorphism analysis is an important historical and still useful molecular technique, but it should be described without exaggeration. It is not a universal way to "test genes," but rather a highly targeted tool for known variants, where the laboratory can reliably distinguish between normal and altered sequences by the length of the fragments after restriction. [45]

Its strengths are accessibility, relative affordability, and clear interpretation in a well-defined task. Its weaknesses include narrow coverage, dependence on a suitable restriction enzyme site, the need for strict controls, and inferiority to modern broad platforms for complex diagnostics. [46]

A modern and honest editorial formulation for the site should be as follows: the method retains practical value for point genotyping, individual tasks of infectious diagnostics and some special laboratory scenarios, but for complex hereditary, tumor and multi-gene clinical questions, priority belongs to broader and more informative sequencing technologies. [47]